ERBB2 and breast carcinoma: In particular, HR-positive/HER2-negative breast cancer cohort was enriched for HER2-low tumors patients in both primary breast cancer and recurrent/metastatic lesions, with HER2-0 tumors instead enriching the triple-negative cohort.